NeOnc Technologies Holdings, Inc. was founded in 2008, driven by our founders’ innovative work in drug delivery for Brain and Central Nervous System (CNS) diseases. Our mission is clear: to significantly advance treatment efficacy for patients facing dire prognoses and low survival rates. The core challenge in CNS therapeutics has always been the Blood-Brain Barrier (BBB), a defense mechanism that has historically prevented effective drug delivery.